Literature DB >> 17977968

Effects of partial deletions within the human immunodeficiency virus type 1 V3 loop on coreceptor tropism and sensitivity to entry inhibitors.

Katrina M Nolan1, Andrea P O Jordan, James A Hoxie.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) V3 loop is critical for coreceptor binding and principally determines tropism for the CCR5 and CXCR4 coreceptors. The recent crystallographic resolution of V3 shows that its base is closely associated with the conserved coreceptor binding site on the gp120 core, whereas more distal regions protrude toward the cell surface, likely mediating interactions with coreceptor extracellular loops. However, these V3-coreceptor interactions and the structural basis for CCR5 or CXCR4 specificity are poorly understood. Using the dual-tropic virus HIV-1(R3A), which uses both CCR5 and CXCR4, we sought to identify subdomains within V3 that selectively mediate R5 or X4 tropism. An extensive panel of V3 mutants was evaluated for effects on tropism and sensitivity to coreceptor antagonists. Mutations on either side of the V3 base (residues 3 to 8 and 26 to 33) ablated R5 tropism and made the resulting X4-tropic Envs more sensitive to the CXCR4 inhibitor AMD3100. When mutations were introduced within the V3 stem, only a deletion of residues 9 to 12 on the N-terminal side ablated X4 tropism. Remarkably, this R5-tropic Delta9-12 mutant was completely resistant to several small-molecule inhibitors of CCR5. Envs with mutations in the V3 crown (residues 13 to 20) remained dual tropic. Similar observations were made for a second dual-tropic isolate, HIV-1(89.6). These findings suggest that V3 subdomains can be identified that differentially affect R5 and X4 tropism and modulate sensitivity to CCR5 and CXCR4 inhibitors. These studies provide a novel approach for probing V3-coreceptor interactions and mechanisms by which these interactions can be inhibited.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17977968      PMCID: PMC2224606          DOI: 10.1128/JVI.01793-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution.

Authors:  J J De Jong; A De Ronde; W Keulen; M Tersmette; J Goudsmit
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

2.  CCR5 interactions with the variable 3 loop of gp120.

Authors:  Kelby B Napier; Zi-xuan Wang; Stephen C Peiper; John O Trent
Journal:  J Mol Model       Date:  2006-05-24       Impact factor: 1.810

3.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.

Authors:  T Dragic; V Litwin; G P Allaway; S R Martin; Y Huang; K A Nagashima; C Cayanan; P J Maddon; R A Koup; J P Moore; W A Paxton
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

4.  A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.

Authors:  C D Rizzuto; R Wyatt; N Hernández-Ramos; Y Sun; P D Kwong; W A Hendrickson; J Sodroski
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728

5.  Core structure of gp41 from the HIV envelope glycoprotein.

Authors:  D C Chan; D Fass; J M Berger; P S Kim
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

6.  Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.

Authors:  Mike Westby; Caroline Smith-Burchnell; Julie Mori; Marilyn Lewis; Michael Mosley; Mark Stockdale; Patrick Dorr; Giuseppe Ciaramella; Manos Perros
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

Review 7.  HIV-1 envelope determinants for cell tropism and chemokine receptor use.

Authors:  T L Hoffman; R W Doms
Journal:  Mol Membr Biol       Date:  1999 Jan-Mar       Impact factor: 2.857

8.  In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.

Authors:  G Scarlatti; E Tresoldi; A Björndal; R Fredriksson; C Colognesi; H K Deng; M S Malnati; A Plebani; A G Siccardi; D R Littman; E M Fenyö; P Lusso
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

9.  Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission.

Authors:  A B van't Wout; N A Kootstra; G A Mulder-Kampinga; N Albrecht-van Lent; H J Scherpbier; J Veenstra; K Boer; R A Coutinho; F Miedema; H Schuitemaker
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

10.  Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.

Authors:  M Dean; M Carrington; C Winkler; G A Huttley; M W Smith; R Allikmets; J J Goedert; S P Buchbinder; E Vittinghoff; E Gomperts; S Donfield; D Vlahov; R Kaslow; A Saah; C Rinaldo; R Detels; S J O'Brien
Journal:  Science       Date:  1996-09-27       Impact factor: 47.728

View more
  28 in total

1.  High affinity CXCR4 inhibitors generated by linking low affinity peptides.

Authors:  Chaozai Zhang; Lina S Huang; Ruohan Zhu; Qian Meng; Siyu Zhu; Yan Xu; Huijun Zhang; Xiong Fang; Xingquan Zhang; Jiao Zhou; Robert T Schooley; Xiaohong Yang; Ziwei Huang; Jing An
Journal:  Eur J Med Chem       Date:  2019-04-01       Impact factor: 6.514

2.  Constrained use of CCR5 on CD4+ lymphocytes by R5X4 HIV-1: efficiency of Env-CCR5 interactions and low CCR5 expression determine a range of restricted CCR5-mediated entry.

Authors:  Lamorris M Loftin; Martha F Kienzle; Yanjie Yi; Benhur Lee; Fang-Hua Lee; Lachlan Gray; Paul R Gorry; Ronald G Collman
Journal:  Virology       Date:  2010-04-09       Impact factor: 3.616

3.  Distinct molecular pathways to X4 tropism for a V3-truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist.

Authors:  Gregory Q Del Prete; George J Leslie; Beth Haggarty; Andrea P O Jordan; Josephine Romano; James A Hoxie
Journal:  J Virol       Date:  2010-06-23       Impact factor: 5.103

4.  Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques.

Authors:  Izabela Bialuk; Stephen Whitney; Vibeke Andresen; Ruth H Florese; Janos Nacsa; Valentina Cecchinato; Valerio W Valeri; Jean-Michel Heraud; Shari Gordon; Robyn Washington Parks; David C Montefiori; David Venzon; Thorsten Demberg; Marjorie Robert- Guroff; Gary Landucci; Donald N Forthal; Genoveffa Franchini
Journal:  Vaccine       Date:  2011-10-27       Impact factor: 3.641

5.  Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41.

Authors:  Cleo G Anastassopoulou; Thomas J Ketas; Rafael S Depetris; Antonia M Thomas; Per Johan Klasse; John P Moore
Journal:  Virology       Date:  2011-02-26       Impact factor: 3.616

6.  Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc.

Authors:  Robert A Ogert; Lei Ba; Yan Hou; Catherine Buontempo; Ping Qiu; Jose Duca; Nicholas Murgolo; Peter Buontempo; Robert Ralston; John A Howe
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

7.  Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4.

Authors:  Caroline Agrawal-Gamse; Fang-Hua Lee; Beth Haggarty; Andrea P O Jordan; Yanjie Yi; Benhur Lee; Ronald G Collman; James A Hoxie; Robert W Doms; Meg M Laakso
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

8.  Different tempo and anatomic location of dual-tropic and X4 virus emergence in a model of R5 simian-human immunodeficiency virus infection.

Authors:  Wuze Ren; Silvana Tasca; Ke Zhuang; Agegnehu Gettie; James Blanchard; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

9.  Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain.

Authors:  Lan Wu; Tongqing Zhou; Zhi-yong Yang; Krisha Svehla; Sijy O'Dell; Mark K Louder; Ling Xu; John R Mascola; Dennis R Burton; James A Hoxie; Robert W Doms; Peter D Kwong; Gary J Nabel
Journal:  J Virol       Date:  2009-03-04       Impact factor: 5.103

10.  Sang Froid in a time of trouble: is a vaccine against HIV possible?

Authors:  Stanley A Plotkin
Journal:  J Int AIDS Soc       Date:  2009-02-02       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.